A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants

J Infect Dis. 1995 Mar;171(3):632-8. doi: 10.1093/infdis/171.3.632.


The safety and immunogenicity of a group A plus group C meningococcal polysaccharide-CRM197 conjugate vaccine was evaluated in 304 8- to 10-week-old Gambian infants. Infants were immunized with one, two, or three doses of conjugate vaccine or with two doses of a meningococcal A plus C polysaccharide vaccine. The conjugate vaccine produced few systemic side effects, and local reactions were similar to those produced by the polysaccharide vaccine. Postvaccination group A meningococcal polysaccharide antibody levels, measured by ELISA, increased progressively after one, two, or three doses of conjugate vaccine. However, one dose of conjugate vaccine given at the age of 6 months induced a higher group C meningococcal antibody response than did two doses of conjugate vaccine given at 2 and 6 months. Two doses of conjugate vaccine induced higher levels of antibody than did two doses of polysaccharide vaccine. Thus, this new meningococcal conjugate vaccine proved to be safe and immunogenic.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bacterial / blood
  • Bacterial Proteins / immunology*
  • Bacterial Vaccines / adverse effects
  • Bacterial Vaccines / immunology*
  • Female
  • Humans
  • Infant
  • Male
  • Meningococcal Vaccines
  • Neisseria meningitidis / immunology*
  • Polysaccharides, Bacterial / immunology*
  • Vaccination
  • Vaccines, Conjugate / immunology


  • Antibodies, Bacterial
  • Bacterial Proteins
  • Bacterial Vaccines
  • Meningococcal Vaccines
  • Polysaccharides, Bacterial
  • Vaccines, Conjugate
  • meningococcal group A polysaccharide
  • meningococcal group C polysaccharide
  • CRM197 (non-toxic variant of diphtheria toxin)